NasdaqCM:CORTPharmaceuticals
Corcept Therapeutics (CORT) Could Be 8% Pricey After Lifyorli Approval And Estimate Upgrades
Corcept Therapeutics (CORT) is back in focus after the FDA approved Lifyorli, its relacorilant combination for platinum resistant ovarian cancer. This development broadens revenue sources beyond flagship drug Korlym.
See our latest analysis for Corcept Therapeutics.
Corcept Therapeutics has seen strong share price momentum, with a 30 day share price return of 16.92% and a 90 day share price return of 107.03%. The 1 year total shareholder return of 39.64% and 5 year total shareholder return of...